Research ArticleOriginal Article
Open Access

Association between body mass index and hemoglobin A1c with serum prostate-specific antigen level

A retrospective cohort study

Wejdan A. Alhamdan, Thamer A. Alsulaiman, Razan I. Alsabti, Ola M. Abdulmowla, Somayh E. Elnaggar and Yaser Alendijani
Saudi Medical Journal September 2023, 44 (9) 870-874; DOI: https://doi.org/10.15537/smj.2023.44.9.20230384

References

  1. 1.↵
    1. Merriel SWD,
    2. Funston G,
    3. Hamilton W.
    Prostate cancer in primary care. Adv Ther 2018; 35: 1285–1294.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Carter HB,
    2. Albertsen PC,
    3. Barry MJ,
    4. Etzioni R,
    5. Freedland SJ,
    6. Greene KL, et al.
    Early detection of prostate cancer: AUA guideline. J Urol 2013; 190: 419–426.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Heidenreich A,
    2. Abrahamsson PA,
    3. Artibani W,
    4. Catto J,
    5. Montorsi F,
    6. Van Poppel H, et al.
    Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol 2013; 64: 347–354.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Hatakeyama S,
    2. Yoneyama T,
    3. Tobisawa Y,
    4. Ohyama C.
    Recent progress and perspectives on prostate cancer biomarkers. Int J Clin Oncol 2017; 22: 214–221.
    OpenUrl
  5. 5.↵
    1. Ochiai A,
    2. Fritsche HA,
    3. Babaian RJ.
    Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology 2005; 66: 819–823.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Chia SE,
    2. Lau WK,
    3. Chin CM,
    4. Tan J,
    5. Ho SH,
    6. Lee J, et al.
    Effect of ageing and body mass index on prostate-specific antigen levels among Chinese men in Singapore from a community-based study. BJU Int 2009; 103: 1487–1491.
    OpenUrlPubMed
  7. 7.↵
    1. Price MM,
    2. Hamilton RJ,
    3. Robertson CN,
    4. Butts MC,
    5. Freedland SJ.
    Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology 2008; 71: 787–791.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Kubota Y,
    2. Seike K,
    3. Maeda S,
    4. Shinohara Y,
    5. Iwata M,
    6. Sugimoto N.
    Relationship between prostate-specific antigen and obesity in prostate cancer screening: analysis of a large cohort in Japan. Int J Urol 2011; 18: 72–75.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Naito M,
    2. Asai Y,
    3. Mori A,
    4. Fukada Y,
    5. Kuwabara M,
    6. Katase S, et al.
    Association of obesity and diabetes with serum prostate-specific antigen levels in Japanese males. Nagoya J Med Sci 2012; 74: 285–292.
    OpenUrlPubMed
  10. 10.
    1. Thompson IM,
    2. Leach R,
    3. Troyer D,
    4. Pollock B,
    5. Naylor S,
    6. Higgins B.
    Relationship of body mass index and prostate specific antigen in a population-based study. Urol Oncol 2004; 22: 127–131.
    OpenUrlPubMed
  11. 11.↵
    1. Kristal AR,
    2. Chi C,
    3. Tangen CM,
    4. Goodman PJ,
    5. Etzioni R,
    6. Thompson IM.
    Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006; 106: 320–328.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. De Nunzio C,
    2. Tubaro A.
    Prostate cancer: diabetes and prostate cancer--an open debate. Nat Rev Urol 2013; 10: 12–14.
    OpenUrl
  13. 13.↵
    1. Bernal-Soriano MC,
    2. Lumbreras B,
    3. Hernández-Aguado I,
    4. Pastor-Valero M,
    5. López-Garrigos M,
    6. Parker LA.
    Untangling the association between prostate-specific antigen and diabetes: a systematic review and meta-analysis. Clin Chem Lab Med 2020; 59: 11–26.
    OpenUrl
  14. 14.↵
    1. Long XJ,
    2. Lin S,
    3. Sun YN,
    4. Zheng ZF.
    Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac J Cancer Prev 2012; 13: 4097–4100.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Cornell S.
    Comparison of the diabetes guidelines from the ADA/EASD and the AACE/ACE. J Am Pharm Assoc (2003) 2017; 57: 261–265.
    OpenUrl
  16. 16.↵
    1. Whelton PK,
    2. Carey RM,
    3. Aronow WS,
    4. Casey DE Jr,
    5. Collins KJ,
    6. Dennison Himmelfarb C, et al.
    2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension 2018; 71: 1269–1324.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Reiter-Brennan C,
    2. Osei AD,
    3. Iftekhar Uddin SM,
    4. Orimoloye OA,
    5. Obisesan OH,
    6. Mirbolouk M, et al.
    ACC/AHA lipid guidelines: personalized care to prevent cardiovascular disease. Cleve Clin J Med 2020; 87: 231–239.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Iguchi K,
    2. Hashimoto M,
    3. Kubota M,
    4. Yamashita S,
    5. Nakamura M,
    6. Usui S, et al.
    Effects of 14 frequently used drugs on prostate-specific antigen expression in prostate cancer LNCaP cells. Oncol Lett 2014; 7: 1665–1668.
    OpenUrl
  19. 19.↵
    1. Chang SL,
    2. Harshman LC,
    3. Presti JC Jr
    . Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 2010; 28: 3951–3957.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Reza HS,
    2. Ali Z,
    3. Tara H,
    4. Ali B.
    Age-specific reference ranges of prostate-specific antigen in the elderly of Amirkola: a population-based study. Asian J Urol 2021; 8: 183–188.
    OpenUrl
  21. 21.↵
    1. Whittemore AS,
    2. Cirillo PM,
    3. Feldman D,
    4. Cohn BA.
    Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol 2005; 174: 872–876.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Bañez LL,
    2. Hamilton RJ,
    3. Partin AW,
    4. Vollmer RT,
    5. Sun L,
    6. Rodriguez C, et al.
    Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275–2280.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Chiu PK,
    2. Wong AY,
    3. Hou SM,
    4. Yip SK,
    5. Ng CF.
    Effect of body mass index on serum prostate-specific antigen levels among patients presenting with lower urinary tract symptoms. Asian Pac J Cancer Prev 2011; 12: 1937–1940.
    OpenUrlPubMed
  24. 24.↵
    1. Andersson B,
    2. Mårin P,
    3. Lissner L,
    4. Vermeulen A,
    5. Björntorp P.
    Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994; 17: 405–411.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Ainahi A,
    2. Brakat A,
    3. Wakrim L,
    4. Mohammadi H,
    5. ElMdaghri N,
    6. Ezzikouri S.
    Prostate-specific antigen levels in Moroccan diabetic males: a cross-sectional study. Curr Diabetes Rev 2018; 14: 286–290.
    OpenUrl
  26. 26.↵
    1. Kobayashi M,
    2. Mizuno T,
    3. Yuki H,
    4. Kambara T,
    5. Betsunoh H,
    6. Nukui A, et al.
    Association between serum prostate-specific antigen level and diabetes, obesity, hypertension, and the laboratory parameters related to glucose tolerance, hepatic function, and lipid profile: implications for modification of prostate-specific antigen threshold. Int J Clin Oncol 2020; 25: 472–478.
    OpenUrl
  27. 27.↵
    1. Müller H,
    2. Raum E,
    3. Rothenbacher D,
    4. Stegmaier C,
    5. Brenner H.
    Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev 2009; 18: 1350–1356.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Wallner LP,
    2. Morgenstern H,
    3. McGree ME,
    4. Jacobson DJ,
    5. St Sauver JL,
    6. Jacobsen SJ, et al.
    The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study. Urology 2011; 77: 137–141.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Fukui M,
    2. Tanaka M,
    3. Kadono M,
    4. Imai S,
    5. Hasegawa G,
    6. Yoshikawa T, et al.
    Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care 2008; 31: 930–931.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Wei C,
    2. Tian L,
    3. Jia B,
    4. Wang M,
    5. Xiong M,
    6. Hu B, et al.
    Association between serum triglycerides and prostate specific antigen (PSA) among U.S. males: National Health and Nutrition Examination Survey (NHANES), 2003-2010. Nutrients 2022; 14: 1325.
    OpenUrl
  31. 31.↵
    1. Bruun L,
    2. Savage C,
    3. Cronin AM,
    4. Hugosson J,
    5. Lilja H,
    6. Christensson A.
    Increase in percent free prostate-specific antigen in men with chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1238–1241.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Akduman B,
    2. Tandberg DJ,
    3. O’Donnell CI,
    4. Hughes A,
    5. Moyad MA,
    6. Crawford ED.
    Effect of statins on serum prostate-specific antigen levels. Urology 2010; 76: 1048–1051.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Prause LW,
    2. Manka L,
    3. Millan C,
    4. Lang E,
    5. Wyler SF,
    6. Grobholz R, et al.
    Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau). World J Urol 2020; 38: 2485–2491.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords